New Data Show Superiority of Abbott's TriClip™ Device Compared to Medical Therapy for Tricuspid Regurgitation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
DexCom drops after Abbott's diabetes sensors cleared for insulin delivery system integration
March 6, 2023 2:24 PM ESTDexCom (NASDAQ: DXCM) shares are down more than 8% Monday afternoon after Abbott (NYSE: ABT) announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated continuous glucose monitoring system sensors for integration with automated insulin delivery systems.
The Libre 2 and 3 sensors track the blood sugar of people with diabetes. This is then monitored via an app on the person's smartphone.
The FDA has cleared the ability for Abbott's modified sensors to integrate with an automated insulin delivery system... More
Evercore ISI Reiterates Outperform Rating on Abbott Labs (ABT), 'a preferential tiering for Libre could position it better for share gains in the larger T2 market'
March 6, 2023 10:19 AM ESTEvercore ISI analyst Vijay Kumar reiterated an Outperform rating and $114.00 price target on Abbott Labs (NYSE: ABT).
The analyst comments "Market opportunity / implications: The T1 market is smalland we would expect ABT to get some incremental share in the T1 market going... More
